Altimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.03 EPS

Altimmune (NASDAQ:ALT) announced its earnings results on Tuesday. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03, Zacks reports. The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. During the same quarter in the previous year, the company earned ($0.39) EPS.

Altimmune Stock Performance

Shares of Altimmune stock traded up $0.42 during trading hours on Wednesday, reaching $9.91. The company’s stock had a trading volume of 8,491,450 shares, compared to its average volume of 3,851,807. The firm has a 50 day moving average price of $6.89 and a 200-day moving average price of $6.87. Altimmune has a one year low of $2.34 and a one year high of $14.84.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. B. Riley restated a “buy” rating and set a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Thursday, August 22nd. Finally, UBS Group began coverage on shares of Altimmune in a report on Tuesday. They issued a “buy” rating and a $26.00 price target on the stock. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the sale, the director now owns 41,958 shares in the company, valued at $289,510.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.10% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.